Blog
RSS FeedPosted by Michael Wonder on 02 Feb 2017
Proposal to list orthopaedic hip and knee implants, cement and associated products on the Pharmaceutical Schedule
2 February 2017 - PHARMAC is seeking feedback on a proposal to list further ranges of orthopaedic implants and associated ...
Posted by Michael Wonder on 02 Feb 2017
Quality over quantity more important in health outcomes
2 February 2017 - When it comes to making a difference in people’s lives, it’s not about how many medicines ...
Posted by Michael Wonder on 02 Feb 2017
AusBiotech consults biotech CEOs on industry advocacy
2 February 2017 - AusBiotech has launched its annual consultation of membership issues, calling for leaders of biotechnology companies to ...
Posted by Michael Wonder on 01 Feb 2017
Senate inquiry on prostheses pricing urged to consider implications
31 January 2017 - AusBiotech has made a submission to the Senate’s Community Affairs References Committee Inquiry into the ‘Price ...
Posted by Michael Wonder on 01 Feb 2017
Advanced ovarian cancer treatment placed on the PBS, a move praised by doctors and patients
1 January 2017 - Women with advanced ovarian cancer can now pay significantly less for a groundbreaking drug, in a ...
Posted by Michael Wonder on 01 Feb 2017
Challenges in the assessment of medical devices: the MedtecHTA project
31 January 2017 - Assessing medical devices raises challenges which require us to reflect on whether current methods are adequate. ...
Posted by Michael Wonder on 31 Jan 2017
Schedule of Pharmaceutical Benefits - 1 February 2017 update
1 February 2017 - The 1 February 2017 issue of the Schedule of Pharmaceutical Benefits sees a number of new ...
Posted by Michael Wonder on 31 Jan 2017
New Zealand Pharmaceutical Schedule - 1 February 2017
1 February 2017 - The February 2017 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Jan 2017
Patients battling deadly ovarian, lung cancer to have affordable access to new drugs
31 January 2017 - Sick patients battling deadly cancers will have affordable access to new drugs which usually cost more ...
Posted by Michael Wonder on 30 Jan 2017
CADTH recommends UCB's Brivlera
25 January 2017 - CADTH's first outcome for 2017 is in favour of the reimbursement of brivaracetam. ...
Posted by Michael Wonder on 30 Jan 2017
Rise in deadly W strain of Meningococcal disease prompts calls for national approach
30 January 2017 - A national approach to the deadly W strain of Meningococcal disease is being considered by Australia's ...
Posted by Michael Wonder on 30 Jan 2017
Cancer drugs price rise 'costing NHS millions'
29 January 2017 - UK prices for generic cancer drugs have risen sharply in the past five years, restricting their ...
Posted by Michael Wonder on 29 Jan 2017
Check your health insurance because extras cover may not be worth it, say experts
29 January 2017 - Private health insurance members with extras cover should be doing a simple maths equation to work ...
Posted by Michael Wonder on 27 Jan 2017
Health insurers, customers hope for a win on premium increases
27 January 2017 - New health minister Greg Hunt could look to score a “win” with consumers and approve the ...
Posted by Michael Wonder on 27 Jan 2017
Post-market review of ezetimibe – draft report
27 January 2017 - Public consultation on the draft Report to the PBAC of the post-market review of ezetimibe is ...